NCT07024329 Implementing REmote SymPtom mOnitoring and maNagement (RESPONd)
| NCT ID | NCT07024329 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Calgary |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,055 participants |
| Start Date | 2025-05-16 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,055 participants in total. It began in 2025-05-16 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to understand if the implementation of a remote symptom monitoring and management program improves outcomes. The program will provide patients the opportunity to complete electronic Patient Reported Outcomes (PROs) questionnaires from home between appointments and receive tailored advice from a study nurse. A second goal of this study is to examine the impact of electronic symptom monitoring on clinic efficiencies. The main question it aims to answer is: • What impact does implementing digitally enabled remote symptom monitoring and management (RESPONd) between ambulatory oncology visits have on patient outcomes and system efficiencies? Participants will: * Report their symptoms and concerns from home by completing the electronic symptom monitoring questionnaire. * Discuss their symptoms and concerns with a study nurse. * Provide feedback about their experience at important timepoints during the study. * Participate as usual in ambulatory clinic appointments.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 * Have cancer * Receiving care in one of the participating clinics. * Able to sign up for MyAHS Connect and consent. * Have access to a digital device at home * Able to complete their electronic PROs questionnaire without support from the clinic team on a weekly (patients on active treatment) or monthly (patients on follow-up) basis, for the duration of the intervention or until they are discharged from the clinic. * Regular access to a telephone in order for the study nurse to call patients to provide symptom management support. Exclusion Criteria: * Patients with cognitive disabilities or who cannot reliably report symptoms independently. * Patients not residing in Alberta, as government-issued ID is required to register for MyAHS Connect. * Patients who do not have regular access to a telephone, as the study nurse needs to be able to call patients to provide symptom management support. * Patients who do not speak English, or who do not have an English-speaking friend, family member, or caregiver to assist them, as the electronic PROs questionnaire is only available in English at this time.
Contact & Investigator
Linda Watson, RN, PhD
PRINCIPAL INVESTIGATOR
Cancer Care Alberta, Alberta Health Services
Frequently Asked Questions
Who can join the NCT07024329 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07024329 currently recruiting?
Yes, NCT07024329 is actively recruiting participants. Contact the research team at chizoba.anyimukwu@albertahealthservices.ca for enrollment information.
Where is the NCT07024329 trial being conducted?
This trial is being conducted at Calgary, Canada, Edmonton, Canada, High River, Canada, Red Deer, Canada.
Who is sponsoring the NCT07024329 clinical trial?
NCT07024329 is sponsored by University of Calgary. The principal investigator is Linda Watson, RN, PhD at Cancer Care Alberta, Alberta Health Services. The trial plans to enroll 1,055 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.